Despite the success of TKIs, there are challenges, such as drug resistance. Mutations in the BCR-ABL gene can lead to resistance against first-line TKIs like imatinib. Therefore, second- and third-generation inhibitors have been developed to overcome resistance, but the emergence of new mutations remains a concern.
